高迁移率族蛋白B1作为白质卒中中少突胶质谱系细胞的自分泌趋化因子
本研究探讨了死亡少突胶质细胞释放的HMGB1作为自分泌趋化因子促进少突胶质前体细胞(OPC)迁移的作用。体外实验表明HMGB1通过TLR2-ERK1/2-FAK轴促进OPC迁移,氧糖剥夺条件培养基也促进迁移;体内白质卒中模型中TLR2敲除小鼠病灶内Olig2(+)细胞少于野生型。作者认为基于HMGB1-TLR2轴的治疗策略可能可行。
要点
- HMGB1通过TLR2而非RAGE促进OPC迁移,下游涉及ERK1/2和FAK磷酸化。
- 氧糖剥夺处理的少突胶质细胞条件培养基促进OPC迁移,提示HMGB1的自分泌趋化功能。
- 体内白质卒中模型中TLR2敲除小鼠病灶内Olig2(+)细胞少于野生型对照。
核心结论
- HMGB1通过TLR2-ERK1/2-FAK轴作为自分泌趋化因子促进OPC迁移,这是髓鞘再生起始且不可或缺的一步。
- 作者认为基于少突胶质谱系中HMGB1-TLR2轴的白质卒中新型治疗策略可能可行。
研究设计与样本
- 体外研究:原代培养OPC的Boyden小室迁移实验,siRNA敲低或药理阻断TLR2、RAGE、Src、ERK1/2和FAK。
- 收集氧糖剥夺处理的少突胶质细胞条件培养基评估对OPC迁移的影响。
- 体内白质卒中模型:使用N5-(1-亚氨基乙基)-L-鸟氨酸(L-NIO)诱导缺血损伤,分析病灶大小和病灶内Olig2(+)细胞数。
主要发现
- HMGB1处理促进OPC迁移,HMGB1拮抗后迁移恢复至未处理水平。
- TLR2敲低而非RAGE敲低减弱HMGB1的促迁移效应。
- TLR2敲低OPC中ERK1/2及其下游分子FAK的磷酸化降低,而Src磷酸化未降低;药理抑制ERK1/2和FAK导致OPC迁移减少。
- 氧糖剥夺条件培养基促进OPC迁移,提示HMGB1的自分泌趋化功能。
- 体内L-NIO诱导缺血损伤后,TLR2(-/-)小鼠病灶内Olig2(+)细胞少于野生型对照,且无论是否给予HMGB1。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The migration of oligodendrocyte precursor cells (OPC) is a key process of remyelination, which is essential for the treatment of white matter stroke. This study aimed to investigate the role of HMGB1 (high mobility group box 1), a damage-associated molecular pattern released from dying oligodendrocytes, as an autocrine chemoattractant that promotes OPC migration. METHODS: The migratory capacity of primary cultured OPCs was measured using the Boyden chamber assay. The downstream pathway of HMGB1-mediated OPC migration was specified by siRNA-induced knockdown or pharmacological blockade of TLR2 (toll-like receptor 2), RAGE (receptor for advanced glycation end product), Src, ERK1/2 (extracellular signal-regulated kinase1/2), and FAK (focal adhesion kinase). Conditioned media were collected from oxygen-glucose deprivation-treated oligodendrocytes, and the impact on OPC migration was assessed. Lesion size and number of intralesional Olig2(+) cells were analyzed in an in vivo model of white matter stroke with N5-(1-iminoethyl)-L-ornithine (L-NIO). RESULTS: HMGB1 treatment promoted OPC migration. HMGB1 antagonism reversed such effects to untreated levels. Among the candidates for the downstream signal of HMGB1-mediated migration, the knockdown of TLR2 rather than that of RAGE attenuated the migration-promoting effect of HMGB1. Further specification of the HMGB1-TLR2 axis revealed that the phosphorylation of ERK1/2 and its downstream molecule FAK, rather than of Src, was decreased in TLR2-knockdown OPCs, and pharmacological inhibition of ERK1/2 and FAK led to decreased OPC migration. Oxygen-glucose deprivation-conditioned media promoted OPC migration, suggesting the autocrine chemoattractant function of HMGB1. In vivo, TLR2(-/-)-mice showed lesser intralesional Olig2(+) cells compared to wild-type controls in response to L-NIO induced ischemic injury regardless of HMGB1 administration. CONCLUSIONS: HMGB1, through the TLR2-ERK1/2-FAK axis, functions as an autocrine chemoattractant to promote OPC migration, which is an initial and indispensable step in remyelination. Thus, a novel treatment strategy for white matter stroke based on the HMGB1-TLR2 axis in the oligodendrocyte lineage could be feasible.
引用
- Choi JY, Jin X, Kim H, et al. High Mobility Group Box 1 as an Autocrine Chemoattractant for Oligodendrocyte Lineage Cells in White Matter Stroke. Stroke. 2022. PMID: 36490365. doi:10.1161/STROKEAHA.122.041414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。